The well-known players in RA pathogenesis and the targets for biological disease modifying antirheumatic drug, TNFα and IL-1β, were recognized as drivers of catabolic signaling in OA joints [2,3]. This evidence concerns the gene IL1B and rheumatoid arthritis.